Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-10-31 6:00 pm Purchase | 13G | Lyell Immunopharma Inc. LYEL | Foresite Capital Fund IV L.P. | 13,683,858 5.300% | 3,683,858 (+36.84%) | View |
| 2024-02-13 2:24 pm Sale | 13G | Aclaris Therapeutics Inc. ACRS | Foresite Capital Fund IV L.P. | 0 0.000% | -4,066,277 (Position Closed) | View |
| 2024-02-13 2:14 pm Purchase | 13G | PHARVARIS N V REGISTERED PHVS | Foresite Capital Fund IV L.P. | 4,038,842 7.800% | 757,774 (+23.10%) | View |
| 2023-05-10 5:20 pm Purchase | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund IV L.P. | 13,718,311 29.500% | 1,780,000 (+14.91%) | View |
| 2023-02-22 3:01 pm Purchase | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund IV L.P. | 11,938,311 25.600% | 1,100,000 (+10.15%) | View |
| 2023-02-13 5:06 pm Purchase | 13G | Aclaris Therapeutics Inc. ACRS | Foresite Capital Fund IV L.P. | 4,066,277 6.100% | 4,066,277 (New Position) | View |
| 2023-02-13 5:02 pm Sale | 13G | Lyell Immunopharma Inc. LYEL | Foresite Capital Fund IV L.P. | 10,000,000 4.000% | -3,282,181 (-24.71%) | View |
| 2023-02-13 4:56 pm Sale | 13G | PHARVARIS N V REGISTERED PHVS | Foresite Capital Fund IV L.P. | 3,281,068 9.700% | -15,000 (-0.46%) | View |
| 2022-06-28 12:37 pm Sale | 13D | QUANTUM-SI INC QSI | Foresite Capital Fund IV L.P. | 4,424,317 3.700% | -4,000,000 (-47.48%) | View |
| 2022-02-11 3:13 pm Sale | 13G | Keros Therapeutics Inc. KROS | Foresite Capital Fund IV L.P. | 0 0.000% | -1,412,705 (Position Closed) | View |
| 2022-02-11 3:12 pm Sale | 13G | PHARVARIS N V REGISTERED PHVS | Foresite Capital Fund IV L.P. | 3,296,068 9.900% | -630,000 (-16.05%) | View |
| 2022-02-11 3:11 pm Sale | 13G | Nurix Therapeutics Inc. NRIX | Foresite Capital Fund IV L.P. | 1,205,798 2.700% | -2,045,051 (-62.91%) | View |
| 2022-02-11 3:10 pm Purchase | 13G | Lyell Immunopharma Inc. LYEL | Foresite Capital Fund IV L.P. | 13,282,181 5.500% | 13,282,181 (New Position) | View |
| 2021-06-21 5:20 pm Purchase | 13D | QUANTUM-SI INC QSI | Foresite Capital Fund IV L.P. | 8,424,317 7.200% | 8,424,317 (New Position) | View |
| 2021-02-16 11:16 am Sale | 13G | Fulcrum Therapeutics Inc. FULC | Foresite Capital Fund IV L.P. | 0 0.000% | -1,500,000 (Position Closed) | View |
| 2021-02-16 11:08 am Purchase | 13G | Nurix Therapeutics Inc. NRIX | Foresite Capital Fund IV L.P. | 3,250,849 8.400% | 90,065 (+2.85%) | View |
| 2021-02-16 10:56 am Sale | 13G | Keros Therapeutics Inc. KROS | Foresite Capital Fund IV L.P. | 1,412,705 6.100% | -15,366 (-1.08%) | View |
| 2021-02-16 10:46 am Sale | 13G | ARBUTUS BIOPHARMA CORP ABUS | Foresite Capital Fund IV L.P. | 0 0.000% | -3,705,128 (Position Closed) | View |
| 2021-02-12 3:26 pm Purchase | 13G | PHARVARIS N V REGISTERED PHVS | Foresite Capital Fund IV L.P. | 3,926,068 12.300% | 3,926,068 (New Position) | View |
| 2020-12-14 9:24 pm Purchase | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund IV L.P. | 10,838,311 25.000% | 10,838,311 (New Position) | View |